Ardelyx - ARDX Stock Forecast, Price & News

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Wall Street Analyst Weigh In

Several analysts have commented on ARDX shares. Cantor Fitzgerald lowered shares of Ardelyx from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $7.00 to $1.00 in a research report on Friday, May 6th. StockNews.com lowered shares of Ardelyx from a "hold" rating to a "sell" rating in a research report on Saturday, August 6th. Piper Sandler decreased their price target on shares of Ardelyx from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Wednesday, May 18th. Finally, Wedbush restated a "neutral" rating on shares of Ardelyx in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $4.83.

Ardelyx Stock Down 1.7 %

Shares of ARDX traded down $0.02 during mid-day trading on Thursday, hitting $0.89. 2,386,720 shares of the company traded hands, compared to its average volume of 3,029,447. Ardelyx has a 1-year low of $0.49 and a 1-year high of $1.92. The company has a market capitalization of $138.28 million, a PE ratio of -0.79 and a beta of 1.84. The business has a 50 day moving average of $0.67 and a 200 day moving average of $0.78.

Ardelyx (NASDAQ:ARDX - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Ardelyx had a negative net margin of 2,594.88% and a negative return on equity of 191.74%. During the same period in the prior year, the firm posted ($0.45) EPS. As a group, research analysts expect that Ardelyx will post -0.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Susan Rodriguez sold 43,920 shares of the stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $28,548.00. Following the transaction, the insider now owns 289,593 shares in the company, valued at approximately $188,235.45. The sale was disclosed in a filing with the SEC, which is available through this link. In other Ardelyx news, insider Susan Rodriguez sold 43,920 shares of the company's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $0.65, for a total value of $28,548.00. Following the sale, the insider now owns 289,593 shares in the company, valued at approximately $188,235.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael Raab sold 103,624 shares of the stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $67,355.60. Following the transaction, the chief executive officer now owns 668,826 shares in the company, valued at approximately $434,736.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 235,185 shares of company stock worth $153,157. 6.00% of the stock is owned by company insiders.